ACRS three-lens brief
Evidence-based stock research on ACRS. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
Moved +4.58% yesterday. · 50-day MA below 200-day MA (death-cross regime); price below both.
- Moved +4.58% yesterday.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 17.1pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $10.36 — 139% above current (11 analysts).
ACRS closed at $4.34 (+4.58%) as of 2026-11-12. Market cap: $688.38M. Price is below the 50-day MA and below the 200-day MA. Positives: moved +4.58% yesterday.; analyst mean target $10.36 — 139% above current (11 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 17.1pp over 30 days.. Last quarter: Revenue $1.48M, net income -$18.51M, free cash flow -$50.13M.
Why three lenses on ACRS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ACRS across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ACRS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ACRS brief"></iframe>